SEC Form 4 · accession 0001209191-17-041302
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan M Peacock
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 22, 2017 · 2:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2017 | A | 2,410 | $0.00 | A | 70,374 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $91.21 | Jun 20, 2017 | A | 8,810 | A | — | Jun 19, 2027 | Common Stock | 8,810 | 8,810 | D |
Explanation of responses
- F1The stock option shall vest in 12 successive equal monthly installments following the date of grant.